Thymosin-ɑ1 for people with chronic hepatitis B.
Cho Naing, Han Ni, Htar Htar Aung et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of thymosin-α1 in treating chronic hepatitis B across 10 randomized controlled trials involving 1349 participants. The analysis suggested that thymosin-α1 may reduce all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96) compared to control interventions, although the evidence was rated as very low certainty.
Key findings
- Thymosin-α1 may reduce all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96) compared to control.
- The review included 10 RCTs with a total of 1349 participants.
- Follow-up durations varied from six months to five years, with a median of 12 months.
- Only two trials reported on comorbidities such as cirrhosis.
Why it matters
Chronic hepatitis B poses significant health risks, including liver failure and cancer. Understanding the potential benefits of thymosin-α1 could inform treatment strategies and improve patient outcomes in this population.
What to keep in mind
The evidence was rated as very low certainty, and the included studies had varying follow-up durations and quality.